2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 055

Referrals Leading to Rheumatologic Diagnosis in a Pediatric Rheumatology Center: Influence of Referring Provider Practice and Training
Abstract Number: 131

Reflections on the Creation of a Transition Clinic and the First 6-months of a Registry for Young Adults with Juvenile Idiopathic Arthritis: The Women’s College Hospital Experience
Abstract Number: 083

Relative Risk of a Thrombotic Event in Janus Kinase Inhibitor Use for JIA using the Epic Cosmos Database
Abstract Number: 117

Reliability of Pediatric-Specific Musculoskeletal Ultrasound Scanning Protocol for the Detection of Arthritis
Abstract Number: 121

Representation of Skin of Color Among Pediatric Images in ACR Image Library
Abstract Number: 130

Resilience, Cumulative Social Disadvantage, and Disease Activity in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 095

Rheum2Fake: Lessons from Severe Nutritional Deficiencies
Abstract Number: 105

Rheumatological Biomarkers and Symptom Progression in Pediatric Systemic Lupus Erythematosus (SLE)
Abstract Number: 113

Risk Assessment for Pediatric Rheumatic Diseases in Children with a History of Kawasaki Disease: A Long-Term Retrospective Comparative Big Data Cohort Study
Abstract Number: 065

Screening for Social Determinants of Health Identifies Differences Based on Insurance Types in a Single Pediatric Rheumatology Division
Abstract Number: 023

Screening Tools for Spondyloarthropathies among Patients with Inflammatory Bowel Disease: A Scoping Review
Abstract Number: 129

Selection of Core Measures in Development of a Childhood Arthritis and Rheumatology Research Alliance based Pediatric Pain Registry for Management of Amplified Musculoskeletal Pain Syndrome
Abstract Number: 127

Setting the Stage for an Effective, Accessible, and Patient-Centered Nature-Based Intervention for Adolescents with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 039

Single-center Experience of Voclosporin Use for Pediatric Lupus Nephritis
Abstract Number: 072

SOCS1 Haploinsufficiency: Functional Evidence Supporting an Expanded Clinical Phenotype

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].